Monogenic forms of b-cell diabetes have been broadly divided according to age of presentation, into neonatal and adolescent/adult forms (the latter previously termed maturity onset diabetes of the young – MODY). Herein we describe the identification of monogenic diabetes in a lady with a long-term history of treatment for type 1 diabetes diagnosed in early adulthood.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care2007;30:S66–73.
2.
MurphyREllardS. Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes. Nat Clin Pract Endocrinol Metab2008;4:200–13.
3.
FraylingTMEvansJCBulmanMP. beta-cell genes and diabetes: molecular and clinical characterization of mutations in transcription factors. Diabetes2001;50:S94–100.
4.
FraylingTMLindgrenCMChevreJC. A genome-wide scan in families with maturity-onset diabetes of the young: evidence for further genetic heterogeneity. Diabetes2003;52:872–81.
5.
WangHAntinozziPA. Molecular targets of a human HNF1a mutation responsible for pancreatic b-cell dysfunction. EMBO J2000;19:4257–64.
6.
RichterSShihDQ. Regulation of apolipoprotein M gene expression by MODY3 gene hepatocyte nuclear factor-1alpha. Diabetes2003;52:2989–95.
7.
ShepherdMPearsonERHoughtonJ. No deterioration in glycemic control in HNF-1 maturity onset diabetes of the young following transfer from long-term insulin to sulphonylureas. Diabetes Care2003;26:3191–92.
8.
TillilHKabberlingJ. Age-corrected empirical genetic risk estimates for first-degree relatives of IDDM patients. Diabetes Care1987;36:93–9.
9.
KleinBEKleinRMossSECruickshanksKJ. Parental history of diabetes in a population-based study. Diabetes Care1996;19:827–30.
